SCHEMBL3250231

SCHEMBL3250231

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(-c4cccnc4)cc3c12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.55
MMP13 P45452 1/20 0.55
MMP14 P50281 1/20 0.55
NR4A2 P43354 1/20 0.54
NPC1 O15118 2/20 0.44
CLEC4M Q9H2X3 1/20 0.42
KDM5A P29375 1/20 0.41
KDM5B Q9UGL1 1/20 0.41
MKNK1 Q9BUB5 1/20 0.41
MKNK2 Q9HBH9 1/20 0.41
TLR8 Q9NR97 1/20 0.41
TLR7 Q9NYK1 1/20 0.41
JAK2 O60674 3/20 0.41
JAK3 P52333 3/20 0.41
DYRK1A Q13627 3/20 0.41
GABRA1 P14867 2/20 0.41
GABRB2 P47870 2/20 0.41
CSF1R P07333 1/20 0.41
RAB9A P51151 1/20 0.41
CLK1 P49759 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3252757 0.88 NPC1 (0.51) NR4A2NPC1CLEC4MJAK2JAK3
SCHEMBL3250086 0.85 JAK2 (0.52) NPC1CLEC4MJAK2JAK3GABRA1
SCHEMBL3250544 0.85 MMP2 (0.48) MMP2MMP13MMP14NR4A2MKNK1
SCHEMBL3241765 0.85 NR4A2 (0.53) NR4A2MKNK1MKNK2DYRK1ACLK1
SCHEMBL3249879 0.85 JAK2 (0.42) NPC1CLEC4MJAK2JAK3GABRA1
SCHEMBL3247523 0.85 CLEC4M (0.46) NPC1CLEC4MJAK2JAK3GABRA1
SCHEMBL3254800 0.84 RIOK2 (0.46) NPC1JAK2JAK3GABRA1GABRB2
SCHEMBL3254531 0.84 CLEC4M (0.45) NPC1CLEC4MJAK2JAK3GABRA1
SCHEMBL3249649 0.83 JAK2 (0.50) NPC1CLEC4MJAK2JAK3GABRA1
SCHEMBL3250598 0.82 JAK2 (0.50) NPC1CLEC4MJAK2JAK3DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 MMP2 1886/4885MMP13 3517/4885MMP14 3170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.